Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 9Gastrointestinal 8Sarcoma 6Genitourinary 6Tumor-Agnostic 4Endocrine 4Other solid neoplasm 3CNS 3Breast 3Head & Neck 2Dermatologic 2NET 1

Conditions

Neoplasms 4

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × cixutumumab × Tumor-Agnostic × Clear all
NCT01007032 2019-02-27

A Study of IMC-A12 in Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
21 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT00785538 2019-01-08

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Eli Lilly and Company

Phase 1 Completed
24 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT00678769 2015-11-04

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
72 enrolled
Tumor-Agnostic

Neoplasms

NCT00785941 2011-10-13

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Eli Lilly and Company

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡